Wideroe 1974

Methods	D: crossover C: unclear B: double WD: 4/30 J: 1‐1‐0 DU: ‐/2x3m (no washout)/‐
Participants	N: 30/26 D: 6 migraine with, 24 without aura C: Ad Hoc F: 87% A: 18‐55 years DU: not reported S: neurology outpatient department in Trondheim, Norway
Interventions	P: 160 mg C: Placebo
Outcomes	R: 1st period: 12/12 vs. 5/14; pooled: 25/26 vs. 10/26 F: mean monthly attack frequency, 1st period: 0.44 (sd 0.52) vs. 1.64 (1.30); pooled: 0.39 (sd 0.48) vs. 1.70 (1.40) AU: not reported HI: not reported AEs: not reported Dropouts‐AEs: not reported V: +
Notes	Included only patients who had responded to propranolol before
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear